rs371447931
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 2P and 0B. PS3_SupportingPM2_Supporting
This summary comes from the ClinGen Evidence Repository: The NM_001482.3:c.845G>A variant in GATM is a missense variant that is predicted to result in the substitution of arginine by histidine at amino acid 282 (p.Arg282His). To our knowledge, this variant has not been reported in an individual with AGAT deficiency in the published literature. The highest population minor allele frequency for this variant in gnomAD v2.1.1 is 0.00003 (1/34578 alleles) in the Latino population, which is lower than the ClinGen CCDS VCEP’s threshold for PM2_Supporting (<0.000055), meeting this criterion (PM2_Supporting). When overexpressed in HeLa cells, the variant resulted in <15% of wild-type GATM enzyme activity (PMID:27233232) (PS3_Supporting). The computational predictor REVEL gives a score of 0.382 which is neither above nor below the thresholds predicting a damaging (>0.75) or benign (<0.15) impact on AGAT function. There is a ClinVar entry for this variant (Variation ID: 225918). In summary, this variant meets the criteria to be classified as a variant of uncertain significance for AGAT deficiency. GATM-specific ACMG/AMP criteria applied, as specified by the ClinGen CCDS VCEP (Specifications Version 1.1.0): PS3_Supporting; PM2_Supporting.(Classification approved by the ClinGen CCDS VCEP on January 24, 2023). LINK:https://erepo.genome.network/evrepo/ui/classification/CA270167214/MONDO:0012996/025
Frequency
Consequence
NM_001482.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GATM | NM_001482.3 | c.845G>A | p.Arg282His | missense_variant | 6/9 | ENST00000396659.8 | NP_001473.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GATM | ENST00000396659.8 | c.845G>A | p.Arg282His | missense_variant | 6/9 | 1 | NM_001482.3 | ENSP00000379895 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152104Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000119 AC: 3AN: 251278Hom.: 0 AF XY: 0.00000736 AC XY: 1AN XY: 135804
GnomAD4 exome AF: 0.00000889 AC: 13AN: 1461678Hom.: 0 Cov.: 32 AF XY: 0.0000124 AC XY: 9AN XY: 727138
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152104Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74304
ClinVar
Submissions by phenotype
not provided Pathogenic:1Other:1
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Mar 05, 2024 | Has not been reported in an individual with clinical features of GATM-related arginine:glycine amidinotransferase deficiency; however in vitro published functional studies for this variant demonstrate it abolishes GATM activity (PMID: 27233232); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 27233232) - |
not provided, no classification provided | in vitro | Hospital for Sick Children | - | - - |
Arginine:glycine amidinotransferase deficiency Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 07, 2022 | This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 282 of the GATM protein (p.Arg282His). This variant is present in population databases (rs371447931, gnomAD 0.003%). This missense change has been observed in individual(s) with Arginine–glycine amidinotransferase (GATM) deficiency (PMID: 27233232). ClinVar contains an entry for this variant (Variation ID: 225918). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). Experimental studies have shown that this missense change affects GATM function (PMID: 27233232). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, reviewed by expert panel | curation | ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel, ClinGen | Jan 24, 2023 | The NM_001482.3:c.845G>A variant in GATM is a missense variant that is predicted to result in the substitution of arginine by histidine at amino acid 282 (p.Arg282His). To our knowledge, this variant has not been reported in an individual with AGAT deficiency in the published literature. The highest population minor allele frequency for this variant in gnomAD v2.1.1 is 0.00003 (1/34578 alleles) in the Latino population, which is lower than the ClinGen CCDS VCEP’s threshold for PM2_Supporting (<0.000055), meeting this criterion (PM2_Supporting). When overexpressed in HeLa cells, the variant resulted in <15% of wild-type GATM enzyme activity (PMID: 27233232) (PS3_Supporting). The computational predictor REVEL gives a score of 0.382 which is neither above nor below the thresholds predicting a damaging (>0.75) or benign (<0.15) impact on AGAT function. There is a ClinVar entry for this variant (Variation ID: 225918). In summary, this variant meets the criteria to be classified as a variant of uncertain significance for AGAT deficiency. GATM-specific ACMG/AMP criteria applied, as specified by the ClinGen CCDS VCEP (Specifications Version 1.1.0): PS3_Supporting; PM2_Supporting. (Classification approved by the ClinGen CCDS VCEP on January 24, 2023). - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 12, 2017 | The p.R282H variant (also known as c.845G>A), located in coding exon 6 of the GATM gene, results from a G to A substitution at nucleotide position 845. The arginine at codon 282 is replaced by histidine, an amino acid with highly similar properties. In one study, authors measured GATM activity of this alteration using liquid chromatography tandem mass spectrometry (LC-MS-MS) and showed that it retained <10% of wild-type GATM activity (DesRoches CL et al. Hum. Mutat., 2016 Sep;37:926-32).This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Arginine:glycine amidinotransferase deficiency;C4551503:Fanconi renotubular syndrome 1 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Sep 01, 2021 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at